Download Library Categories Annual General MeetingAnnual ReportsCorporate Governance*Corporate PresentationsFact SheetInterim ReportsPodcastsResearch Presentations & PapersWebcasts Year None2018201720162015201420132012201120102009200820072006200520042003200220012000 Document Type Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients - EHA Abstract - May 2018 (Adams) Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients - EHA Abstract - May 2018 (Adams) Kempen Life Sciences Conference - April 2018 Kempen Life Sciences Conference - April 2018 AGM 2018 Presentation AGM 2018 Presentation Remuneration Principles Remuneration Principles Articles of Association dated February 28, 2018 Articles of Association dated February 28, 2018 Resumé 2017 Resumé 2017 Annual Report Overview 2017 Annual Report Overview 2017 Statutory Corporate Governance Report 2017 Statutory Corporate Governance Report 2017 Election Results of the Annual General Meeting 2018 Election Results of the Annual General Meeting 2018 J.P. Morgan Healthcare Conference - January 2018 J.P. Morgan Healthcare Conference - January 2018 Investor Presentation, January 2018 Investor Presentation, January 2018 Genmab 2017 Annual Report Genmab 2017 Annual Report Genmab Full Year 2017 Results Podcast Genmab Full Year 2017 Results Podcast Full Year 2017 Results Presentation Full Year 2017 Results Presentation Statutory Report on Corporate Social Responsibility 2017 Statutory Report on Corporate Social Responsibility 2017 Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH abstract -Nove Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH abstract -Nove Genmab's 2017 R&D Update - December 2017 Genmab's 2017 R&D Update - December 2017 Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in CASTOR Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in CASTOR Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX Daratumumab, Lenalidomide and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone Versus Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for High Dose Therapy (HDT) and Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone Versus Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for High Dose Therapy (HDT) and Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX, a Phase III Randomized Study Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX, a Phase III Randomized Study Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase Ib Study Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase Ib Study Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results of an Open-label, Phase I/II Study Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results of an Open-label, Phase I/II Study Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) in Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001 Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) in Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001 Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-label, Phase Ib Study Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-label, Phase Ib Study Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
